In this study, we investigated the correlation between FGF23/D-serine and hearing impairment in MHD patients with ESRD, which is expected to provide a theoretical basis for the treatment of hearing impairment induced by chronic renal failure and a potential target for drug therapy. The gene discussed is FGF23; the disease is hearing loss disorder.